FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2158681922> ?p ?o ?g. }

• W2158681922 endingPage "466" @default.
• W2158681922 startingPage "459" @default.
• W2158681922 abstract "Background In 2004, a randomised phase III trial by the European Organisation for Research and Treatment of Cancer (EORTC) and National Cancer Institute of Canada Clinical Trials Group (NCIC) reported improved median and 2-year survival for patients with glioblastoma treated with concomitant and adjuvant temozolomide and radiotherapy. We report the final results with a median follow-up of more than 5 years. Methods Adult patients with newly diagnosed glioblastoma were randomly assigned to receive either standard radiotherapy or identical radiotherapy with concomitant temozolomide followed by up to six cycles of adjuvant temozolomide. The methylation status of the methyl-guanine methyl transferase gene, MGMT, was determined retrospectively from the tumour tissue of 206 patients. The primary endpoint was overall survival. Analyses were by intention to treat. This trial is registered with Clinicaltrials.gov, number NCT00006353. Findings Between Aug 17, 2000, and March 22, 2002, 573 patients were assigned to treatment. 278 (97%) of 286 patients in the radiotherapy alone group and 254 (89%) of 287 in the combined-treatment group died during 5 years of follow-up. Overall survival was 27·2% (95% CI 22·2–32·5) at 2 years, 16·0% (12·0–20·6) at 3 years, 12·1% (8·5–16·4) at 4 years, and 9·8% (6·4–14·0) at 5 years with temozolomide, versus 10·9% (7·6–14·8), 4·4% (2·4–7·2), 3·0% (1·4–5·7), and 1·9% (0·6–4·4) with radiotherapy alone (hazard ratio 0·6, 95% CI 0·5–0·7; p<0·0001). A benefit of combined therapy was recorded in all clinical prognostic subgroups, including patients aged 60–70 years. Methylation of the MGMT promoter was the strongest predictor for outcome and benefit from temozolomide chemotherapy. Interpretation Benefits of adjuvant temozolomide with radiotherapy lasted throughout 5 years of follow-up. A few patients in favourable prognostic categories survive longer than 5 years. MGMT methylation status identifies patients most likely to benefit from the addition of temozolomide. Funding EORTC, NCIC, Nélia and Amadeo Barletta Foundation, Schering-Plough." @default.
• W2158681922 created "2016-06-24" @default.
• W2158681922 creator A5000695802 @default.
• W2158681922 creator A5005840478 @default.
• W2158681922 creator A5006238946 @default.
• W2158681922 creator A5006549117 @default.
• W2158681922 creator A5007347096 @default.
• W2158681922 creator A5008091556 @default.
• W2158681922 creator A5010891460 @default.
• W2158681922 creator A5012084917 @default.
• W2158681922 creator A5012753378 @default.
• W2158681922 creator A5014218178 @default.
• W2158681922 creator A5017177249 @default.
• W2158681922 creator A5033909956 @default.
• W2158681922 creator A5038129366 @default.
• W2158681922 creator A5048627921 @default.
• W2158681922 creator A5050961926 @default.
• W2158681922 creator A5053052330 @default.
• W2158681922 creator A5053746026 @default.
• W2158681922 creator A5056837393 @default.
• W2158681922 creator A5058982388 @default.
• W2158681922 creator A5059715152 @default.
• W2158681922 creator A5063513320 @default.
• W2158681922 creator A5075595989 @default.
• W2158681922 creator A5087905831 @default.
• W2158681922 creator A5089856175 @default.
• W2158681922 date "2009-05-01" @default.
• W2158681922 modified "2023-10-16" @default.
• W2158681922 title "Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial" @default.
• W2158681922 cites W1918200890 @default.
• W2158681922 cites W1976520103 @default.
• W2158681922 cites W1977392502 @default.
• W2158681922 cites W1982388856 @default.
• W2158681922 cites W1988299559 @default.
• W2158681922 cites W1999476677 @default.
• W2158681922 cites W2000366267 @default.
• W2158681922 cites W2001660159 @default.
• W2158681922 cites W2014323633 @default.
• W2158681922 cites W2017985800 @default.
• W2158681922 cites W2023002553 @default.
• W2158681922 cites W2036044314 @default.
• W2158681922 cites W2036560693 @default.
• W2158681922 cites W2047710431 @default.
• W2158681922 cites W2059624809 @default.
• W2158681922 cites W2066346982 @default.
• W2158681922 cites W2068220280 @default.
• W2158681922 cites W2082471832 @default.
• W2158681922 cites W2085054454 @default.
• W2158681922 cites W2086216067 @default.
• W2158681922 cites W2088446974 @default.
• W2158681922 cites W2093783077 @default.
• W2158681922 cites W2096287682 @default.
• W2158681922 cites W2105100844 @default.
• W2158681922 cites W2107055927 @default.
• W2158681922 cites W2112014411 @default.
• W2158681922 cites W2114012083 @default.
• W2158681922 cites W2115516828 @default.
• W2158681922 cites W2120872266 @default.
• W2158681922 cites W2121625674 @default.
• W2158681922 cites W2125372543 @default.
• W2158681922 cites W2125643269 @default.
• W2158681922 cites W2131981377 @default.
• W2158681922 cites W2136527161 @default.
• W2158681922 cites W2139008103 @default.
• W2158681922 cites W2140859993 @default.
• W2158681922 cites W2145517527 @default.
• W2158681922 cites W2147535764 @default.
• W2158681922 cites W2158370459 @default.
• W2158681922 cites W2164774264 @default.
• W2158681922 cites W2167713837 @default.
• W2158681922 cites W2170367762 @default.
• W2158681922 cites W2328946792 @default.
• W2158681922 cites W4231637567 @default.
• W2158681922 cites W4244344354 @default.
• W2158681922 doi "https://doi.org/10.1016/s1470-2045(09)70025-7" @default.
• W2158681922 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19269895" @default.
• W2158681922 hasPublicationYear "2009" @default.
• W2158681922 type Work @default.
• W2158681922 sameAs 2158681922 @default.
• W2158681922 citedByCount "6127" @default.
• W2158681922 countsByYear W21586819222012 @default.
• W2158681922 countsByYear W21586819222013 @default.
• W2158681922 countsByYear W21586819222014 @default.
• W2158681922 countsByYear W21586819222015 @default.
• W2158681922 countsByYear W21586819222016 @default.
• W2158681922 countsByYear W21586819222017 @default.
• W2158681922 countsByYear W21586819222018 @default.
• W2158681922 countsByYear W21586819222019 @default.
• W2158681922 countsByYear W21586819222020 @default.
• W2158681922 countsByYear W21586819222021 @default.
• W2158681922 countsByYear W21586819222022 @default.
• W2158681922 countsByYear W21586819222023 @default.
• W2158681922 crossrefType "journal-article" @default.
• W2158681922 hasAuthorship W2158681922A5000695802 @default.
• W2158681922 hasAuthorship W2158681922A5005840478 @default.
• W2158681922 hasAuthorship W2158681922A5006238946 @default.
• W2158681922 hasAuthorship W2158681922A5006549117 @default.
• W2158681922 hasAuthorship W2158681922A5007347096 @default.

• next